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The Emperor Has No Symptoms: The Risks of a
Blanket Approach to Using Epinephrine
Autoinjectors for All Allergic Reactions
Paul J. Turner, FRACP, PhDa,b, Audrey DunnGalvin, PhDc, and Jonathan O’B. Hourihane, MD, DMd London, United
Kingdom; New South Wales, Australia; and Cork, Ireland
Fatal anaphylaxis in humans is rare and unpredictable. We note
a trend to provide allergic individuals with care plans that
recommend immediate use of epinephrine autoinjectors if
allergen ingestion is suspected, even in the absence of any allergic
symptoms, without any supporting evidence base. Instructions
to use an autoinjector device, irrespective of reaction severity and
especially when symptoms are actually absent, are likely to add
to parental and patient anxiety. Of greater concern is the
possibility of epinephrine being administered “too early” to treat
initial, mild symptoms that then progress to severe anaphylaxis.
It is not hard to visualize a scenario where one or both
epinephrine autoinjectors have been deployed for mild
symptoms, yet the reaction progresses to a severe reaction and no
further epinephrine is available for administration. Epinephrine
needs to be available as a rescue treatment for anaphylaxis,
potentially buying valuable minutes while emergency medical
services are activated to attend. Food-allergic individuals and
their carers need to be provided with more constructive strategies
and support than merely being told to “use your pen.”  2016
The Authors. Published by Elsevier Inc. on behalf of the
American Academy of Allergy, Asthma & Immunology. This is
an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/). (J Allergy Clin Immunol
Pract 2016;4:1143-6)
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A new emergency care plan for food-allergic individuals was
published by the Food Allergy Research & Education (FARE)
earlier this year. We ﬁnd some elements in the plan1 contro-
versial, and are unaware of the evidence base on which some of
the directives (Figure 1) have been promulgated, particularly the
recommendation to administer epinephrine even in the absence
of symptoms.
It is very difﬁcult to determine whether an allergic individual
is “extremely reactive” or not. The term “reactivity” causes
confusion: does it refer to dose sensitivity (or threshold) to
allergen, or severity of the elicited reaction? Most individuals who
react to food allergens at the bottom of the dose response curve
(derived from food challenge data) experience only mild re-
actions.2,3 Furthermore, data suggest that individuals with a
history of anaphylaxis are not more dose sensitive than those
without a history of anaphylaxis.4-7 The vast majority of fatal
reactions are due to substantial levels of exposure accidentally
ingested, often with other signiﬁcant cofactors present contrib-
uting to the severity of the reaction.8-10
Anaphylaxis to food is not uncommon11; however, fatal food-
induced anaphylaxis is very rare, with a case fatality rate at
<0.0001%.12,13 Data suggest that, in many cases, anaphylaxis
(admittedly at the less severe end of the anaphylaxis spectrum)
resolves without any treatment14—a daily event in many emer-
gency departments (ED), where patients present having experi-
enced symptoms of anaphylaxis but failed to use their
autoinjector or have not had their anaphylaxis correctly diag-
nosed in the ED. Arguably, our biggest challenge in the man-
agement of food-allergic individuals is in identifying those who
are most at risk of severe, life-threatening reactions; although
fatal anaphylaxis is rare, it is also very unpredictable.11 As a result,
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Abbreviations used
ED- Emergency departments
EMS- Emergency medical services
we have to apply the same management strategies to all food-
allergic individuals, resulting in the widespread provision of
rescue medication including epinephrine autoinjectors to anyone
considered to be at risk of anaphylaxis. That in itself is a further
challenge; the limited published data imply that up to 3 quarters
of peanut-allergic children will have anaphylaxis if exposed to
sufﬁcient allergen.15
CAN USING EPINEPHRINE AUTOINJECTORS FOR
MILD ALLERGIC SYMPTOMS CAUSE HARM?
We believe that the use of epinephrine for any exposure to an
allergen is overtreatment, and may, paradoxically, place some
individuals at greater risk of severe outcomes. The concept of
“very early” epinephrine, given immediately at the onset of any
symptom seems to be overinvasive medical advice, which has
implications for negative patient perception of the burden in
managing daily life with this condition. One can argue that given
the difﬁculty for patients in identifying their own symptoms of
anaphylaxis,16,17 it may simplify management by advising
epinephrine to be administered for all reactions. However, given
the tendency of patients, and their parents, not to use epineph-
rine autoinjectors even when appropriate to do so14—often out
of anxiety for the consequences of an injection and/or underlying
needle phobia—we would be concerned that a lowering of the
threshold to give epinephrine would only increase the reluctance
of individuals to administer an injection, even when it is war-
ranted. Similar to the widespread use of precautionary allergen
labelling on food packaging, blanket strategies often give rise to
greater, rather than less risky behaviors.
We are concerned that a recommendation to use epinephrine
autoinjectors for any symptoms of an allergic reaction might be
driven, in part, by commercial interests. The patient literature
provided by at least one manufacturer of epinephrine auto-
injectors appears to imply that the device should be used for
“critical symptoms,” which according to the instructions include
mouth swelling and skin symptoms.18 This trend or “slippage”—
where nonsevere symptoms are labeled “critical”—is concerning;
guidelines and patient literature should be written by non-
conﬂicted individuals with appropriate expertise, and not driven
by a marketing agenda. From a patient perspective, this may
further compound confusion over what constitutes “anaphy-
laxis,” giving rise to stress and anxiety, particularly for parents of
young children.19,20
Delayed use of epinephrine in evolving anaphylaxis has
been associated with adverse outcomes including death.8,9
Epinephrine is generally well tolerated by most individuals,
even children, who receive it intramuscularly,21,22 and, of course,
we do encourage our patients to use their epinephrine auto-
injector if they have signs of airway/respiratory or cardiovascular
involvement, or if they are uncertain what to do, because of
difﬁculty in recognizing or identifying symptoms in themselves
or in their child. We also advocate epinephrine use in the context
of a rapidly progressing reaction. However, we do not advise
patients to inject epinephrine for urticaria or angioedema,
because, if they occur in isolation or rather in the absence of
other symptoms or signs, they are nearly always minor self-
limiting symptoms that, in our view, do not justify epinephrine
injection. One also has to consider that tremor and/or shaking is
not uncommon after epinephrine autoinjector use22; this can be
justiﬁed in the context of treating anaphylaxis, but if used for
mild reactions, the allergic individual may develop a reluctance to
use epinephrine that impacts on the decision to treat subsequent
reactions—including anaphylaxis—with appropriate rescue
medication.
Food-allergic individuals often receive differing advice on their
level of reactivity from clinicians, who themselves have differing
levels of expertise and experience of food allergy and anaphylaxis,
which, incidentally, are not the same thing.23 A food-allergic
individual’s perception of his and/or her own risk—and likeli-
hood of reaction—may differ from that of an experienced
clinician. Parents are understandably motivated to protect their
own child to the greatest possible extent in their role as parents,
but the allergy literature is now full of reports of disproportionate
parental anxiety impacting adversely on family life, interpersonal
relationships, and general social functioning.19,20,24 Instructions
to use an autoinjector device, irrespective of severity and espe-
cially when symptoms are actually absent, are likely to add to
parental and patient anxiety; this is maladaptive and counter-
productive, in that it results in lower self-efﬁcacy and compe-
tence in emergency care,25,26 in turn leading to a greater adverse
impact on food allergy-related quality of life.
The idea that consumption of any amount of allergen (eg,
peanut) should motivate immediate administration of epineph-
rine, even when no symptoms have been elicited, is very
controversial. Up to 50% of challenge-proven peanut-allergic
individuals do not react to doses up to 100 mg of peanut protein
(about half a peanut),3-5 although we acknowledge that the
formal challenge scenario is an artiﬁcial setting and that com-
munity reactions may involve other covariables. In the panic
caused by possible exposure, it can be difﬁcult to discern whether
true exposure has occurred. If a peanut-allergic individual has
inadvertently eaten a candy bar and only then notices a “may
contain” warning, should that individual be instructed to self-
administer epinephrine? Almost two thirds of prepacked con-
fectionery are labeled with some form of precautionary allergen
label.27 The majority of nut-allergic individuals will eat some of
FIGURE 1. Extract from the Food Allergy Research & Education (FARE) emergency self-care plan.1
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these products.28,29 A blanket policy of epinephrine adminis-
tration in the absence of any symptoms is a step too far.
Our biggest concern is that the data from case series of fatal
food-induced anaphylaxis have reported a median time to
cardiorespiratory arrest (from consumption of the allergen) of
around 30 minutes.30 The plasma half-life of epinephrine is 2-3
minutes, although intramuscular injection prolongs this. It is
therefore conceivable that epinephrine administered “too early”
may limit management options if used to treat initial, mild
symptoms that then progress (with gastrointestinal absorption) to
severe anaphylaxis. Epinephrine autoinjectors are frequently used
incorrectly31,32 or have failed for technical reasons, resulting in
epinephrine not being administered; this is likely to have
contributed to fatal outcomes in some cases.9 It is not hard to
visualize a scenario where one or both epinephrine autoinjectors
have been deployed for mild symptoms, yet the reaction pro-
gresses to a severe reaction and no further epinephrine is available
for administration. This scenario may be even more likely to
occur in the context of an individual administering the auto-
injector to a child. One might argue that because users are
advised to contact emergency medical services (EMS) after the
use of an autoinjector, a lack of further epinephrine autoinjectors
is less of an issue. However, in practice, allergic individuals do
not always contact EMS in a timely manner, if at all33; where the
health system levies a charge for EMS, this may not always be
covered by health insurance and may thus provide a further
disincentive to activate EMS.34 Furthermore, EMS response
times vary, with average times from initial contact to arrival on
scene of around 9 minutes in the USA35 and Europe.36 Thus,
50% of response times are longer than this, and these times do
not include time to summon EMS nor the time taken to locate
the patient after arrival at the address provided to EMS. It is
therefore entirely feasible that there will be occasions when EMS
support is delayed, and thus further epinephrine is not available
in the context of an ongoing anaphylactic reaction.
There are no human reports or studies using animal models that
show that “early” or “hyper-soon” epinephrine aborts what
could—at least in animal studies—be considered inevitable or
certain anaphylaxis. Indeed, there is at least one case report of a
patient who was repeatedly administered epinephrine during an
initially mild allergic reaction to brazil nut, which did not prevent
progression to fatal respiratory arrest.30 Furthermore, up to one
third of fatalities due to food-induced anaphylaxis are administered
at least one dose of epinephrine in a timely manner, and yet the
outcome is still death.8,9 We note that the fatality rate for cases of
food-induced anaphylaxis admitted to intensive care units for
cardiorespiratory intervention (ie, artiﬁcial ventilation and
inotropic support) is very low.37 Severe anaphylaxis will respond to
intensive management, and self-administered epinephrine is a
critical intervention to prolong the window of opportunity for this
to occur. Premature administration of epinephrine may be coun-
terproductive, reducing the time available for medical intervention.
Early use of epinephrine autoinjectors may increase the rates
of adverse outcomes (by increasing the numbers of autoinjector
devices actually deployed); this could impair public and medical
conﬁdence in evidence-based self-care plans, and even in the
advice and advocacy provided by health care professionals. Pre-
sumably, the advice we are contesting here is a well-meant
blanket policy, to protect those who may not receive sufﬁcient
and appropriate education in understanding and implementing
expert-developed, evidence-based self-care plans. Such patients,
and those caring for them, are likely to be “deﬁcient” in self-
efﬁcacy—less able to manage an allergic reaction appropriately,
and advised to overtreat themselves with a medical device they
may have been inexpertly coached to use properly—all of which
makes misuse more likely. “Crying wolf” may become an issue;
“cases” that are treated—but were never “cases” at all—may
diminish ﬁrst-responder reactions to “cases” that are “real.” This
is not just hypothetical; in the UK, there are ongoing concerns as
to whether the EMS response to anaphylaxis will be downgraded
in priority,38 a situation likely to be exacerbated with “hyper-
soon” epinephrine use.
CONCLUSIONS
In humans, where fatal anaphylaxis is rare and unpredictable,
we contend that a care plan that recommends the use of
epinephrine autoinjectors, in the absence of any symptoms of an
allergic reaction, is ill-advised and not based on any supporting
evidence. Epinephrine needs to be available as a rescue treatment
for anaphylaxis, potentially buying valuable minutes while EMS
are activated to attend. Food-allergic individuals and their carers
need to be provided with more constructive strategies and sup-
port than merely being told to “use your pen.”
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